Copyright
©The Author(s) 2019.
World J Clin Oncol. Feb 24, 2019; 10(2): 38-51
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.38
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.38
Table 1 Summary of selected publications reporting stereotactic body radiation therapy for mixed and bones oligometastatic prostate cancer
Ref. | Study type | No. patients/lesions | No. of metastases | Imaging method | Site of metastases | SBRT schedules | LC | PFS |
Mixed | ||||||||
Jereczek-Fossa et al[56] | R | 34/38 | Single pelvic LN and/or single distant lesion | CT, BS, Choline PET | Bone, LN, local recurrence | 30-36 Gy/3-5 fr | 88% (16.9 mo) | 42.6% (30 mo) |
Ahmed et al[49] | P | 17/21 | ≤ 5 | Choline PET/CT, MRI, CT | Bone, LN, Liver | Median dose 20 Gy (8-24 Gy/1-3 fr), 50 Gy/5 fr (LN), 60 Gy/3 fr (Liver) | 100% (6 mo) | 74% (6 mo), 40% (1 yr) |
Berkovic et al[45] | R | 24/29 | ≤ 3 | BS, 18F-FDG PET/TC, Choline PET/TC | Bone, LN | Median dose 50 Gy (40-50)/8-10 fr | 100% (2 yr) | 72% (1 yr), 42% (2 yr) |
Decaestecker et al[34] | P | 50/70 | ≤ 3 | 18F-FDG PET/TC, Choline PET/TC | Bone, LN, Viscera | 50 Gy/10 fr, 30 Gy/3 fr | 100% (2 yr) | 64% (1 yr), 35% (2 yr) |
Pasqualetti et al[57] | P | 29/45 | ≤ 3 | Choline PET/CT | Bone, LN | 24 Gy/1 fr, 27 Gy/3 fr | Median 11.5 mo | NR |
Muldermans et al[30] | R | 66/81 | < 5 | Choline PET/CT, MRI, CT, BS | Bone, LN, Liver | Median dose 16 Gy (16-24)/1 fr, 30 Gy/3 fr, 50 Gy/5 fr | 82% (2 yr) | 45% (2 yr) |
Bouman-Wammes et al[48] | R | 43/54 | ≤ 4 | Choline PET/CT | Bone, LN | 30 Gy/3 fr, 45 Gy/3 fr, 35 Gy/5 fr | NR | Median 31.5 mo |
Triggiani et al[47] | R | OR: 100/139, OP: 41/70 | ≤ 3 | OR: Choline PET, CT and BS, OP: Choline PET, CT/scintigraphy | Bone, LN | BED 116 (80–216.6) Gy | OR: 92.8% (2 yr), OP: 90.2% (2 yr) | OR: 43% (2 yr), OP: 22% (2 yr) |
Pasqualetti et al[46] | P | 51/78 | ≤ 5 | Choline PET/CT | Bone, LN | 24 Gy/1 fr, 27 Gy/3 fr | 98.7% (1 yr), 97.4% (2 yr) | NR |
Ost et al[20] (STOMP) | P | Surveillance: 31/65, MDT: 31/51 | ≤ 3 | Choline PET/CT | Extracranial | N = 25 SBRT 30 Gy/3 fr | Median FU (3 yr), MDT: 100%, Surveillance: 19.3% | NR |
Siva et al[26] (POPSTART) | P | 33 /50 | ≤ 3 | CT/BS /18F-NaF PET | Bone, LN | 20 Gy/1 fr | 97% (1 yr), 93% (2 yr) | 58% (1 yr), 39% (2 yr) |
Conde et al[50] | P | 67 (100) | ≤ 4 | Choline PET/CT, NMR Diffusion | Bone, LN | 45 Gy/6 fr, 30 Gy/3 fr | 100% (Median FU 9 mo) | Median 21 mo, OR: 22.9 mo, OP: 8.7 mo |
Bone | ||||||||
Muacevic et al[31] | P | 40/64 | ≤ 2 | Choline PET/CT | Bone | Mean dose 20.2 Gy (16.5-22 Gy)/1 fr | 95.5% (2 yr) | NR |
Habl et al[58] | R | 15/20 | ≤ 5 | Choline PET/CT, 68Ga-PSMA-PET | Bone | 25-35 Gy/5 fr | 100% (2 yr) | Median 7.3 mo |
Fanetti et al[59] | R | 55/77 | ≤ 5 | Choline-PET/CT, MRI, CT, 68Ga-PSMA-PET/CT | Bone | 24 Gy/3 fr (+ frequent) | 83% (1 yr) | 56% (1 yr) |
Table 2 Summary of selected publications reporting stereotactic body radiation therapy for lymph nodes oligometastatic prostate cancer
Ref. | Study type | No. Patients / lesions | No. of metastases | Imaging method | Site of metastases | SBRT schedules | LC | PFS |
Lymph node | ||||||||
Casamassima et al[33] | R | 25/25 | NR | Cholina PET/CT | LN | N = 18: 30 Gy/3 fr | 90% (3 yr) | Median 24 mo |
Detti et al[36] | R | 30/39 | NR | Cholina PET/CT | LN | 24-36 Gy/1-5 fr | 100% (1 yr) | NR |
Ponti et al[60] | R | 16/18 | ≤ 2 | Cholina PET/CT | LN | 12-35 Gy/1-5 fr | 94% (2 yr) | NR |
Ost et al[29] | R | 72/89 | ≤ 3 | 18F-FDG, Cholina PET/CT,MRI | LN | At least 5 Gy/fr with BED at least 80 Gy | 95.8% (3 yr) | Median 21 mo 34% (3 yr) 13% (5 yr) |
Ingrosso et al[61] | R | 40/47 | NR | Cholina PET/CT | LN | 35-40 Gy/5 fr (+ frequent) | 98% (mean FU 30 mo) | NR |
Jereczek-Fossa et al[62] | R | 94/124 | ≤ 5 | Cholina PET/CT/CT/MRI | LN | 24-30 Gy/3 fr (+ frequent) | 84% (2 yr) | 30% (2 yr) |
Table 3 Summary of clinical trials investigating treatment with stereotactic body radiation therapy in oligometastatic prostate cancer
Study | Study type | Type of patient | No. of metastases | Site of metastases | Intervention | Primary endpoint |
NCT02680587 Sidney, Kimmel Comprehensive Cancer Center (ORIOLE)[51] | Phase II | HS | ≤ 3 | Bone or soft tissue | Observation vs SBRT | Time to progression (Time Frame: 6 mo) |
NCT02759783 Royal Marsden Hospital (CORE)[53] | Phase II/III | HS/CR | ≤ 3 | Extracranial | Standard of Care vs SBRT | Progression Free Survival (Time Frame: 60 mo post treatment) |
NCT03569241 PEACE V (STORM) Ghent[54] | Phase II | HS | ≤ 3 | Pelvic LN | MDT (salvage lymph node dissection or SBRT) vs MDT + WPRT. ADT (6 mo in the two arms) | Metastases-free survival (Time Frame: 2 yr) |
NCT02685397 PCS IX[55] | Phase II/III | CR | ≤ 4 | Any location excluding brain and liver metastasis | LHRH agonist + Enzalutamide vs LHRH agonist + Enzalutamide + SBRT | Radiographic Progression-free Survival (Time Frame: 5 yr) |
NCT03361735 City of Hope Medical Center[63] | Phase II | HS | ≤ 4 | Bone. One lung lesion < 2 cm allowed | ADT + SBRT + Radium Ra223 dichloride | Time to treatment failure (Time Frame: Assessed up to 5 yr) |
NCT01818986 Southwestern Medical Center Texas[64] | Phase II | CR | Any number of metastatic site are allowed. However, only up to six sites will be selected for SBRT | Any location except brain metastasis | Sipuleucel-T and SBRT | Time to progression (Time Frame: 4 yr) |
NCT02816983 Mayo Clinic Rochester[65] | Phase II | CR | ≤ 3 | Any location | SBRT | PSA-progression free survival (Time Frame: 1 yr) Overall Survival (Time Frame: 2 yr) |
NCT02192788 GICOR Castellon[66] | Phase II | HS/CR | ≤ 4 | Bone or LN | SBRT | No. of patients without disease progression (Time Frame: 5 yr) |
- Citation: Palacios-Eito A, Béjar-Luque A, Rodríguez-Liñán M, García-Cabezas S. Oligometastases in prostate cancer: Ablative treatment. World J Clin Oncol 2019; 10(2): 38-51
- URL: https://www.wjgnet.com/2218-4333/full/v10/i2/38.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i2.38